Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | IL6ST | P40189 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 7/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695123 | 1.00 | PPARA (0.47) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL20695126 | 1.00 | PPARA (0.47) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL19423252 | 1.00 | PPARA (0.47) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL20695124 | 1.00 | PPARA (0.47) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL6597608 | 0.94 | PPARA (0.47) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL13986788 | 0.93 | PPARA (0.47) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL20708959 | 0.87 | PPARA (0.40) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL22793540 | 0.87 | PPARA (0.41) | PPARAIL6STFAAHNAAAIDH1 | |
| SCHEMBL30984038 | 0.86 | IL6ST (0.56) | IL6STFAAHNAAAIDH1AGTR2 | |
| SCHEMBL21724415 | 0.85 | PPARA (0.52) | PPARAIL6STFAAHNAAAIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440046-B | Synthetic method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest phyllocladia persica | 塔里木大学 | 2022-09-16 | — | — | CN | claimed |
| CN-111440046-A | Synthesis method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest peach leaf miner | 塔里木大学 | 2020-07-24 | — | — | CN | claimed |
| CN-111440046-B | Synthetic method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest phyllocladia persica | 塔里木大学 | 2022-09-16 | — | — | CN | disclosed |
| EP-3437640-B1 | AGENT FOR TREATING SYNUCLEINOPATHY | UNIV TOHOKU (JP) | 2021-11-24 | — | — | EP | disclosed |
| EP-3437640-B1 | AGENT FOR TREATING SYNUCLEINOPATHY | UNIV TOHOKU (JP) | 2021-11-24 | — | — | EP | disclosed |
| CN-111440046-A | Synthesis method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest peach leaf miner | 塔里木大学 | 2020-07-24 | — | — | CN | disclosed |
| US-10709688-B2 | Agent for treating synucleinopathy | TOHOKU UNIVERSITY (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10709688-B2 | Agent for treating synucleinopathy | TOHOKU UNIVERSITY (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | TOHOKU UNIVERSITY (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | TOHOKU UNIVERSITY (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3437640-A1 | SYNUCLEINOPATHY THERAPEUTIC MEDICATION | Tohoku University (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3437640-A1 | SYNUCLEINOPATHY THERAPEUTIC MEDICATION | Tohoku University (JP) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017171053-A1 | SYNUCLEINOPATHY THERAPEUTIC MEDICATION | 国立大学法人東北大学 | 2017-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709688-B2 | Agent for treating synucleinopathy | SNCA, PARK7, SYNJ1 | PPARA 2175/4885IL6ST 4310/4885FAAH 1647/4885 |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | SNCA, PARK7, SYNJ1 | PPARA 2175/4885IL6ST 4310/4885FAAH 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.